The main objective of this project is to obtain a new innovative and effective anti-tumour drug, and to bring it to the market through a validated personalised medicine process, alongside a diagnostic tool to identify patients who may benefit from the therapy.

The first sub-objective of the project is to focus on the study of the efficacy of compounds with the highest cytotoxicity in screening assays using cell line libraries for three specific tumour types: NSCLC, TNBC, and malignant mesothelioma. These three tumour types, in which YAP1 alteration has been identified, belong to the group of tumours with the lowest five-year survival rate, which means that potential advances in the limited treatment options are vitally important for patients.